The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
REHOVOT, Israel and RALEIGH, N.C., July 31, 2015 (GLOBE NEWSWIRE) -- As announced today by Bayer HealthCare, the U.S. Food & Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. Finacea® Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea® Foam.
"The approval of Finacea® Foam is an important milestone for Foamix, as this is the first prescription product developed using our technology to be FDA approved for sale in the United States," said Dov Tamarkin, Chief Executive Officer of Foamix Pharmaceuticals. "We are proud of the progress made in our partnership with Bayer, and pleased that this product will be available to help people living with mild to moderate papulopustular rosacea."
Finacea® Foam will be available by prescription beginning September 2015, and will be marketed in the United States by Bayer HealthCare.
About Finacea® (azelaic acid) Foam, 15%
Finacea® (azelaic acid) Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Important Safety Information - Warnings and Precautions
Skin Reactions: There have been isolated reports of hypopigmentation after use of azelaic acid. Because azelaic acid has not been well studied in patients with dark complexion, monitor these patients for early signs of hypopigmentation.
Eye and Mucous Membranes Irritation: Azelaic acid has been reported to cause irritation of the eyes. Avoid contact with the eyes, mouth and other mucous membranes. If Finacea® Foam does come in contact with the eyes, wash the eyes with large amounts of water and consult a healthcare professional if eye irritation persists.
Flammability: The propellant in Finacea® Foam is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C).
Most Common Adverse Reactions
In clinical studies, the most frequently observed adverse reactions in ≥ 0.5% of subjects treated with Finacea® Foam included local site pain (6.2%), pruritus (severe itching) (2.5%), dryness (0.7%), and erythema (redness) (0.7%).
For Topical Use Only
Finacea® Foam is not for oral, ophthalmic or intravaginal use.
Avoid the use of occlusive dressings or wrappings at the application site. Avoid use of alcoholic cleansers, tinctures and astringents, abrasives and peeling agents.
Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
For important risk and use information, see the full Prescribing Information at
Rosacea is a chronic cutaneous disorder primarily affecting the contours of the central face. There is no known cure. Rosacea is most frequently seen in adults between 30 and 50 years of age. Although the exact root cause of rosacea remains unknown, both genetic and environmental factors are thought to have an impact on causing this disease. To learn more about rosacea, please visit www.rosacea.org.
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.